Nocturnal scratch and sleep disturbance in patients with atopic dermatitis: Performance of digital outcomes from baricitinib phase III clinical trials

Abstract In clinical trials, itch and sleep disturbances associated with atopic dermatitis (AD) are typically assessed using subjective patient-reported outcomes (PROs). This study explored the clinical validity of algorithms that derive digital scratch and sleep outcomes from actigraphy data in patients with AD. Algorithms that had previously shown good agreement with video annotation/polysomnography (“gold standard”) data were applied to actigraphy data from 664 adults with moderate-to-severe AD in two phase III monotherapy studies of baricitinib (BREEZE-AD1 and -AD2). The algorithm-determined percentage of the “total sleep opportunity” (period spent sleeping/attempting to sleep) spent asleep was moderately correlated with nocturnal scratch (r=-0.45), with scratch explaining »25% of sleep variation. Patients in the lowest quartile for mean hourly nocturnal scratch duration spent 23% more of their total sleep opportunity asleep, and 107 fewer minutes/night awake after initially falling asleep, than those in the highest quartile. Digital outcomes and PROs for itch/scratch and sleep disturbance were weakly correlated (r<0.30). Both PROs and digital endpoints significantly improved with baricitinib 4 mg whereas placebo treatment led to improvements in PROs but no improvement of digital outcomes. Findings from this evolving technology indicate that objective digital endpoints can provide clinically relevant insights that complement PROs.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-11514435/v1
Primary Topic
Dermatology and Skin Diseases
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Nocturnal scratch and sleep disturbance in patients with atopic dermatitis: Performance of digital outcomes from baricitinib phase III clinical trials

Jonathan I. Silverberg, Amy S. Paller, Najwa Somani, Lisa Cirri et al.
Research Square
Dermatology and Skin Diseases
preprint

Nocturnal scratch and sleep disturbance in patients with atopic dermatitis: Performance of digital outcomes from baricitinib phase III clinical trials

Jonathan I. Silverberg, Amy S. Paller, Najwa Somani, Lisa Cirri, Sreekumar G Pillai, Hui Zhang, Emma Guttman-Yassky, Brian Winger, Ju Ji
preprint en

Abstract

Abstract In clinical trials, itch and sleep disturbances associated with atopic dermatitis (AD) are typically assessed using subjective patient-reported outcomes (PROs). This study explored the clinical validity of algorithms that derive digital scratch and sleep outcomes from actigraphy data in patients with AD. Algorithms that had previously shown good agreement with video annotation/polysomnography (“gold standard”) data were applied to actigraphy data from 664 adults with moderate-to-severe AD in two phase III monotherapy studies of baricitinib (BREEZE-AD1 and -AD2). The algorithm-determined percentage of the “total sleep opportunity” (period spent sleeping/attempting to sleep) spent asleep was moderately correlated with nocturnal scratch (r=-0.45), with scratch explaining »25% of sleep variation. Patients in the lowest quartile for mean hourly nocturnal scratch duration spent 23% more of their total sleep opportunity asleep, and 107 fewer minutes/night awake after initially falling asleep, than those in the highest quartile. Digital outcomes and PROs for itch/scratch and sleep disturbance were weakly correlated (r<0.30). Both PROs and digital endpoints significantly improved with baricitinib 4 mg whereas placebo treatment led to improvements in PROs but no improvement of digital outcomes. Findings from this evolving technology indicate that objective digital endpoints can provide clinically relevant insights that complement PROs.

Research Square
Northwestern University (US), Mount Sinai Hospital (CA), Mount Sinai Hospital (US), Eli Lilly (United States) (US), George Washington University (US)
Eli Lilly and Company, Incyte
Good health and well-being
Dermatology and Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon